Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMB-003 in Healthy Volunteers
NCT07798505Phase 1Recruiting
- Sponsor
- Hemab Therapeutics
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial in bleeding disorder comparing HMB-003 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 42 days. Started Aug 2026; status: recruiting.
02
Drugs
HMB-003
03
Conditions
bleeding disorder
Beyond the preview
Go deeper on NCT07798505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07798505.